DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06779929

Completed

Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Comparative Study of Tirzepatide vs Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Assets

Dulaglutide / Semaglutide / Tirzepatide

Listed sites

1

Recruiting sites

—

Enrollment

70,000

actual

Study population

Cardiovascular disease, Type 2 diabetes

Key I/E criterion

•Established ASCVD

Primary endpoint

•Expanded / custom MACE composite (Myocardial infarction (any), Stroke (any), All-cause death)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06779929
Org study ID2024P001317

Timeline

Milestones

Study start2024-11-01actual
Study first posted2025-01-17actual
Primary completion2025-12-01actual
Study completion2026-03-01actual
Last update posted2026-05-15actual

Assets

Investigational agents

DulaglutideSemaglutideTirzepatide

Study populations

Who this study enrolls

Cardiovascular diseaseType 2 diabetes

Eligibility

Who can enroll

Minimum age40 Years
SexAll
Sampling methodNon probability sample

Study population text

Patients \> 40 years old with T2D and established atherosclerotic cardiovascular disease.

Inclusion criteria

•Patients with T2D who were new users of tirzepatide or new users of dulaglutide
•AND established ASCVD defined as:
–History of Myocardial Infarction (MI) or MI sequela
–Unstable or stable angina
–Coronary atherosclerosis disease or procedures
–Ischemic stroke
–Peripheral arterial disease or procedures
–Atherosclerotic cerebrovascular disease or cerebrovascular procedures
–Lower-limb amputation
•Age >= 40 years old
•Patients with at least 180 days of continuous health plan enrollment before and including the treatment initiation date

Exclusion criteria

•Patients with Type 1 diabetes mellitus
•Patients with missing age or sex information
•Patients with history of proliferative diabetic retinopathy, panretinal photocoagulation, vitreous hemorrhage, or intravitreal anti-VEGF injection
•Patient within history of left ventricular assisted device (LVAD) or heart transplant
•Patients with any previous organ transplants
•Patients with acute of chronic pancreatitis
•Patients with gastroparesis, bowel obstruction or bariatric surgery
•Patient with CKD Stage 5, end stage kidney disease, kidney transplant, or hemodialysis
•Patients with multiple endocrine neoplasm syndrome type 2 (MEN-2)
•Patient with cancer
•Pregnant women
•Patient with diabetic ketoacidosis or HONK within the last year to treatment initiation
•Patients with acute hepatitis within the last year to treatment initiation
•Patients with elevated serum calcitonin level within the last year to treatment initiation
•Previous exposure to GLP-1RA or pramlintide during the 180-days washout period and including treatment initiation date
•Patients with severe hypoglycemia within the last 6 months to treatment initiation
•Patients with hospitalization for heart failure within the last 60 days to treatment initiation
•Patient with acute coronary syndrome, ischemic stroke, peripheral arterial disease, or coronary or cerebrovascular procedure within the last 60 days to treatment initiation
•Patients with prescription dispensing for both tirzepatide and dulaglutide on treatment initiation date

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Cardiovascular outcomes

1 endpoint
Primary/protocol endpoint

Composite CV outcome

Time frame:From treatment initiation to end of follow up, up to 48 months.

Expanded / custom MACE composite

composite event, event

componentsMyocardial infarction (any), Stroke (any), All-cause death

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.